23andMe shares tank as the DNA testing company files for bankruptcy
23andMe, once the pioneer of consumer genetic testing, saw its stock crumble more than 46% Monday morning after filing for Chapter 11 bankruptcy. The company, which saw a peak valuation of $6 billion just a few years ago, now faces a financial crisis as it grapples with dwindling demand and major operational setbacks.
Founded in 2006, 23andMe’s rise to prominence was fueled by its DNA testing kits, offering individuals a chance to find out their genetic makeup. But despite its initial popularity, the company never turned a profit, and its market value plummeted to under $50 million by 2024.
Its troubles were compounded by a data breach in 2023 that exposed nearly 7 million users’ personal information. Last year, the company rejected a take-private from cofounder and CEO Anne Wojcicki, who said she would step down from her role as the company focuses on restructuring. In November, the company announced it would cut 40% of its workforce and halted its therapeutic development plans.